NCT06944717View on ClinicalTrials.gov

A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 3, 2025

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2026

Conditions
Norovirus Infections
Interventions
BIOLOGICAL

VXA-G1.1-NN

Legacy vaccine, administered orally.

BIOLOGICAL

VXA-G2.4-NS

Legacy vaccine, administered orally.

BIOLOGICAL

VXA G1.1 NN-T

Next generation vaccine, administered orally.

BIOLOGICAL

VXA G2.4 NS-T

Next generation vaccine, administered orally.

Trial Locations (1)

66219

Johnson County Clin Trials - JCCT, Lenexa

Sponsors

Lead Sponsor

Vaxart
All Listed Sponsors
lead

Vaxart

INDUSTRY

NCT06944717 - A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old | Biotech Hunter | Biotech Hunter